alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 25 studies in Cognitive tests and assessment published 2014 · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Cognitive tests and assessment” covers

Cognitive tests and assessment — Memory and thinking tests, screening tools and rating scales: how well they measure what they claim to.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The Study of Mental and Resistance Training (SMART) study—resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Journal of the American Medical Directors Association 2014-10-23

Mild cognitive impairment (MCI) increases dementia risk with no pharmacologic treatment available. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Predictors of cognitive impairment in an early stage Parkinson's disease cohort

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Movement disorders : official journal of the Movement Disorder Society 2014-01-06

The impact of Parkinson's disease (PD) dementia is substantial and has major functional and socioeconomic consequences. 4 key findings →

Design: longitudinal study Participants: 486 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. BMC neurology 2014-01-15

A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. 4 key findings →

Design: clinical trial Participants: 399 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Because of the aging population and a rise in the number of stroke survivors, the prevalence of post-stroke cognitive impairment (PSCI) is increasing. 4 key findings →

Design: cohort study Participants: 280 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014-08-15

Delirium is a profound neuropsychiatric disturbance precipitated by acute illness. 4 key findings →

Design: longitudinal study Participants: 465 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Movement disorders : official journal of the Movement Disorder Society 2014-11-07

Cognitive impairment is one of the earliest, most common, and most disabling non-motor symptoms in Parkinson's disease (PD). 4 key findings →

Design: cohort study Participants: 360 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Knowledge on survival in dementia is crucial for patients and public health planning. 4 key findings →

Participants: 15,209 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Molecular psychiatry 2014-03-11

This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of neurology, neurosurgery, and psychiatry 2014-06-04

Elevated CSF τ is considered a biomarker of neuronal injury in newly developed Alzheimer's disease (AD) and mild cognitive impairment (MCI) criteria. 4 key findings →

Participants: 24 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Montreal Cognitive Assessment (MoCA) - a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients

✓ Peer-reviewed alzhub usefulness score 49 out of 100. PloS one 2014-10-27

Chronic kidney disease (CKD) patients undergoing hemodialysis (HD) therapy have an increased risk of developing cognitive impairment and dementia, which are known relevant factors in disease prognosis and therapeutic success, but still lack adequate screening in clinical routine. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of neurology, neurosurgery, and psychiatry 2014-08-13

Moreover, we found, in either the whole AD population or both subgroups, a CSF profile in which higher 4 key findings →

Participants: 145 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Feasibility and validity of the self-administered computerized assessment of mild cognitive impairment with older primary care patients

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer disease and associated disorders 2014-10-01

We investigated whether a validated computerized cognitive test, the Computerized Assessment of Mild Cognitive Impairment (CAMCI), could be independently completed by older primary care patients. 1 key finding →

Participants: 130 Evidence: low

Full summary, score breakdown and related studies → Original source

Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of neurology 2014-07-25

Similar to Alzheimer's disease (AD), dementia with Lewy bodies (DLB) is characterized by a profound degeneration of cortically-projecting cholinergic neurons of the basal forebrain (BF) and associated depletion of cortical cholinergic activity. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2014-08-20

The Montreal Cognitive Assessment (MoCA) is a brief cognitive screening instrument developed by Nasreddine et al. to detect mild cognitive impairment, a high-risk condition for Alzheimer's disease and other forms of dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Archives of gerontology and geriatrics 2014-10-18

We investigated possible abnormalities in the retinal nerve fiber layer (RNFL) and macula lutea of patients diagnosed with Alzheimer's disease (AD) and mild cognitive impairment (MCI) and tested for any correlation with the severity of dementia. 4 key findings →

Participants: 72 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Can a novel computerized cognitive screening test provide additional information for early detection of Alzheimer's disease?

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-03-18

Compared with ERP, MRI, or neuropsychological tests alone, the VR-DOT could provide additional predictive information in a low-cost, computerized, and noninvasive way. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed